Acute Reactogenicity after Intramuscular Immunization with Recombinant Vesicular Stomatitis Virus Is Linked to Production of IL-1β

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Athearn, Kathleen ^a   Sample, Christopher J ^a   Barefoot, Brice E ^a   Williams, Kristi L ^a   Ramsburg, Elizabeth A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADAPTOR PROTEIN ASC; INFLAMMASOME; INFLAMMASOME ADAPTOR MOLECULE ASC; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIVE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACUTE DISEASE; ACUTE REACTOGENICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MEGADOSE; DRUG RECHALLENGE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-1BETA; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-1; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84867312659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046516     Document Type: Article

References (58)

1. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK, (2001) Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75: 11079-11087.
2. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, et al. (2005) Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340: 174-182.
3. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367: 1399-1404.
4. Barefoot BE, Sample CJ, Ramsburg EA, (2009) Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol 16: 488-498.
5. Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, et al. (2009) Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 27: 893-903.
6. Wollmann G, Tattersall P, van den Pol AN, (2005) Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol 79: 6005-6022.
7. Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN, (2008) Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28: 1882-1893.
8. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
9. Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, et al. (2008) Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 68: 4506-4510.
10. Johnson KM, Vogel JE, Peralta PH, (1966) Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 15: 244-246.
11. Fields BN, Hawkins K, (1967) Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med 277: 989-994.
12. Tesh RB, Peralta PH, Johnson KM, (1969) Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity. Am J Epidemiol 90: 255-261.
13. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, et al. (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72: 4704-4711.
14. Publicover J, Ramsburg E, Robek M, Rose JK, (2006) Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol 80: 7028-7036.
15. MacKenzie D, (2009) Ebola accident puts vaccine to the test. New Scientist pp. 4.
16. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, et al. (1995) Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 3: 9-19.
17. Fantuzzi G, Dinarello CA, (1996) The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 59: 489-493.
18. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, et al. (1998) Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187: 1463-1475.
19. Lesnikov VA, Efremov OM, Korneva EA, Van Damme J, Billiau A, (1991) Fever produced by intrahypothalamic injection of interleukin-1 and interleukin-6. Cytokine 3: 195-198.
20. Higashi S, Ohishi H, Kudo I, (2000) Augmented prostaglandin E2 generation resulting from increased activities of cytosolic and secretory phospholipase A2 and induction of cyclooxygenase-2 in interleukin-1 beta-stimulated rat calvarial cells during the mineralizing phase. Inflamm Res 49: 102-111.
21. Angel J, Berenbaum F, Le Denmat C, Nevalainen T, Masliah J, et al. (1994) Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur J Biochem 226: 125-131.
22. Poeck H, Bscheider M, Gross O, Finger K, Roth S, et al. (2010) Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 11: 63-69.
23. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A, (2009) Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 206: 79-87.
24. Van Bleek GM, Nathenson SG, (1990) Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 348: 213-216.
25. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, et al. (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356: 768-774.
26. Kostura MJ, Tocci MJ, Limjuco G, Chin J, Cameron P, et al. (1989) Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl Acad Sci U S A 86: 5227-5231.
27. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, et al. (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science 256: 97-100.
28. Schonbeck U, Mach F, Libby P, (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161: 3340-3346.
29. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, et al. (1999) Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A 96: 6261-6266.
30. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS, (1991) Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 174: 821-825.
31. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
32. Brydon L, Walker C, Wawrzyniak A, Whitehead D, Okamura H, et al. (2009) Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 23: 217-224.
33. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, et al. (2002) Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346: 1265-1274.
34. Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R, (1999) Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 18: 42-48.
35. Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, et al. (2004) MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 292: 351-357.
36. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, et al. (2005) Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 294: 2720-2725.
37. Wicker S, Rabenau HF, Doerr HW, Allwinn R, (2009) Influenza vaccination compliance among health care workers in a German university hospital. Infection 37: 197-202.
38. Opstelten W, Hak E, Verheij TJ, van Essen GA, (2001) Introducing a pneumococcal vaccine to an existing influenza immunization program: vaccination rates and predictors of noncompliance. Am J Med 111: 474-479.
39. Velan B, Kaplan G, Ziv A, Boyko V, Lerner-Geva L, (2011) Major motives in non-acceptance of A/H1N1 flu vaccination: the weight of rational assessment. Vaccine 29: 1173-1179.
40. Farez MF, Correale J, (2011) Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis. Arch Neurol.
41. Stanley SL Jr, Frey SE, Taillon-Miller P, Guo J, Miller RD, et al. (2007) The immunogenetics of smallpox vaccination. J Infect Dis 196: 212-219.
42. Plakhov IV, Arlund EE, Aoki C, Reiss CS, (1995) The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 209: 257-262.
43. Clarke DK, Nasar F, Lee M, Johnson JE, Wright K, et al. (2007) Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 81: 2056-2064.
44. Finck BN, Johnson RW, (1997) Anorexia, weight loss and increased plasma interleukin-6 caused by chronic intracerebroventricular infusion of interleukin-1beta in the rat. Brain Res 761: 333-337.
45. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, et al. (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471-475.
46. Dinarello CA, (2011) A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 41: 1203-1217.
47. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD, (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29: 301-305.
48. Lachmann HJ, Quartier P, So A, Hawkins PN, (2011) The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 63: 314-324.
49. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, et al. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13: 851-856.
50. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, et al. (2009) Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 31: 110-121.
51. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, et al. (2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-107.
52. Rajan JV, Rodriguez D, Miao EA, Aderem A, (2011) The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. J Virol 85: 4167-4172.
53. Schmitz N, Kurrer M, Bachmann MF, Kopf M, (2005) Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 79: 6441-6448.
54. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, et al. (2009) The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30: 556-565.
55. Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, et al. (2009) The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30: 566-575.
56. Ramsburg EA, Publicover JM, Coppock D, Rose JK, (2007) Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent. J Immunol 178: 6350-6358.
57. Furst DE, (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26: 1960-1975.
58. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, et al. (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63: 545-555.